Physician profile
Russell E Dodson
NPI 1760475354
$783.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $31.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $183.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $173.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.31 | 2021 | |
| Pfizer INC. | $56.69 | 2021 | |
| Lilly USA, LLC | $54.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.60 | 2021-2022 | |
| Abbvie INC. | $33.38 | 2021 | |
| Novo Nordisk INC | $31.21 | 2021 | |
| Mylan Specialty L.P. | $21.57 | 2021 | |
| Amgen INC. | $18.83 | 2021 | |
| Eisai INC. | $18.07 | 2021 | |
| Vistapharm, INC. | $14.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.